Opinion|Videos|February 27, 2025
Overview of BTK Inhibitors in Development for CSU Treatment
Panelists discuss how newer Bruton tyrosine kinase (BTK) inhibitors being developed for chronic spontaneous urticaria (CSU), particularly remibrutinib (in phase 3 trials) and rilzabrutinib (in phase 2), are designed to be more selective than earlier oncology-focused BTK inhibitors, potentially reducing off-target effects like bleeding, cardiovascular complications, and GI issues.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s talk a bit about the BTK inhibitors currently being developed and studied for the treatment of CSU:
- Remibrutinib: phase 3 trials, with 12-, 24-, and 52-week data available; inhibits BTK in mast cells, basophils, and B cells
- Rilzabrutinib: currently in phase 2 trials
- How do the BTK inhibitors under development for CSU treatment differ from earlier generations of BTK inhibitors used in oncology and other autoimmune diseases?
- Older BTK inhibitors have limited selectivity and irreversibly inhibit additional kinases, increasing potential for off-target adverse effects (AEs; bleeding effects, cardiotoxicity [hypertension, atrial fibrillation], gastrointestinal effects, and rash).
- Remibrutinib binds to the inactive conformation of BTK and shows higher selectivity, limiting the potential for these off-target AEs
Advertisement
Related to this article
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
3
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5